Economic consequences of established rheumatoid arthritis and its treatment

Best Practice and Research: Clinical Rheumatology

Volumn 21, Issue 5, 2007, Pages 929-942

  Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biologic agents; pharmacoeconomics; rheumatoid arthritis; TNF inhibitors; value

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

ATHEROSCLEROSIS; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG DOSE REDUCTION; DRUG UTILIZATION; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; JOINT INJURY; OUTCOME ASSESSMENT; PHYSICAL DISABILITY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HEALTH POLICY; HUMANS; MODELS, ECONOMIC;

EID: 34548496019     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2007.05.005     Document Type: Review

References (64)

1. Pincus T., Kavanaugh A., and Sokka T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the 'side effects' or risks of RA leads to underestimation of the benefit/risk of therapies. Clinical and Experimental Rheumatology 22 supplement 35 (2004) S2-S11
2. Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. The New England Journal of Medicine 340 (1999) 253-259
3. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
4. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. The New England Journal of Medicine 343 (2000) 1594-1602
5. Genovese M.C., Bathon J.M., Martin R.W., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis and Rheumatism 46 (2002) 1443-1450
6. van de Putte L.B., Rau R., Breedveld F.C., et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals of the Rheumatic Diseases 62 (2003) 1168-1177
7. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatism 48 (2003) 35-45
8. Maini R.N., Breedveld F.C., Kalden J.R., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism 50 (2004) 1051-1065
9. Klareskog L., van der Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
10. Keystone E., Kavanaugh A., Sharp J., et al. Radiographic, clinical, and functional outcomes with adalimumab (a human anti-TNF alpha monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methotrexate theapy: a randomized, controlled, 52 week-trial. Arthritis and Rheumatism 50 (2004) 1400-1411
11. Kavanaugh A., Cohen S., and Cush J. The evolving use of TNF inhibitors in rheumatoid arthritis. The Journal of Rheumatology 31 (2004) 1881-1884
12. Wong J. Cost-effectiveness of anti-tumor necrosis factor agents. Clinical and Experimental Rheumatology 22 supplement 35 (2005) S65-S70
13. Lambert C.M. Medical therapy for rheumatoid arthritis-value for money?. Rheumatology 40 (2001) 961-964
14. Hurst N.P., and Forbes J. Does economic evaluation have anything to offer the rheumatologist?. Rheumatology 38 (1999) 2-5
15. Ruff B. OMERACT: Economic evaluations and health policy. The Journal of Rheumatology 26 (1999) 2076-2077
16. Gabriel S., Tugwell P., O'Brien B., et al. Report of the OMERACT Task Force on Economic Evaluation. Outcome Measures in Rheumatology. The Journal of Rheumatology 26 (1999) 203-206
17. Solomon D., and Maetzel A. Pharmacoeconomics of prescribing for rheumatoid arthritis. International Journal of Advances in Rheumatology 2 (2004) 91-96
18. Weisman M., Gano A., Gabriel S., et al. Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal. The Journal of Rheumatology 30 (2003) 1739-1747
19. Wolfe F., Michaud K., and Pincus T. Do rheumatology cost-effectiveness analyses make sense?. Rheumatology 43 (2004) 4-6
20. Maetzel A. Cost-effectiveness analysis: out of touch with clinical reality?. Arthritis and Rheumatism (Arthritis Care and Research) 53 (2005) 3-4
21. Verstappen S.M.M., Boonen A., Verkleij H., et al. Productivity costs among patients with rheumatoid arthritis: The influence of methods and sources to value loss of productivity. Annals of the Rheumatic Diseases 64 (2005) 1754-1760
22. Rat A.-C., and Boissier M.-C. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 71 (2004) 518-524
23. Tan M.C., Regier D.A., Esdaile J.M., et al. Health economic evaluation: a primer for the practicing rheumatologist. Arthritis and Rheumatism (Arthritis Care and Research) 55 (2006) 648-656
24. Gabriel S.E., Crowson C.S., and O'Fallon W.M. Mortality in rheumatoid arthritis: have we made an impact in 4 decades?. The Journal of Rheumatology 26 (1999) 2529-2533
25. Pincus T., Sokka T., and Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis and Rheumatism 44 (2001) 1234-1236
26. Gabriel S.E., Crowson C.S., Kremers H.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis and Rheumatism 48 (2003) 54-58
27. Pincus T., Brooks R.H., and Callahan L.F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Annals of Internal Medicine 120 (1994) 26-34
28. Jantti J., Aho K., Kaarela K., and Kautiainen H. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. Rheumatology 38 (1999) 1138-1141
29. Fex E., Larsson B.M., Nived K., and Eberhardt K. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. The Journal of Rheumatology 25 (1998) 44-50
30. Zink A., Braun J., Listing J., and Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German Rheumatological Database. The Journal of Rheumatology 27 (2000) 613-622
31. Sokka T., Krishnan E., Hakkinen A., and Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis and Rheumatism 48 (2003) 59-63
32. Wiles N.J., Scott D.G., Barrett E.M., et al. Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Annals of the Rheumatic Diseases 60 (2001) 956-961
33. Verstappen S.M.M., Bijlsma J.W.J., Verkleij H., et al. Overview of work disability in rheumatoid arthritis patients as observed in crossectional and longitudinal surveys. Arthritis and Rheumatism (Arthritis Care and Research) 51 (2004) 488-497
34. Birrell F.N., Hassell A.B., Jones P.W., and Dawes P.T. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clinical Rheumatology 19 (2000) 195-199
35. Wolfe F. The prognosis of rheumatoid arthritis: assessment of disease activity and disease severity in the clinic. The American Journal of Medicine 103 (1997) 12S-18S
36. Gabriel S.E., Crowson C.S., Campion M.E., and O'Fallon W.M. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. The Journal of Rheumatology 24 (1997) 43-48
37. Lajas C., Abasolo L., Bellajdel B., et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence based study. Arthritis and Rheumatism (Arthritis Care and Research) 49 (2003) 64-70
38. Dunlop D., Manheim L., Yelin E., et al. The costs of arthritis. Arthritis and Rheumatism (Arthritis Care and Research) 49 (2003) 101-113
39. Huscher D., Merkesdal S., Thiele K., et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Annals of the Rheumatic Diseases 65 (2006) 1175-1183
40. Cooper N.J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 39 (2000) 28-33
41. Yelin E., and Wanke L.A. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis and Rheumatism 42 (1999) 1209-1218
42. Fries J.F. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Annals of the Rheumatic Diseases 58 (1999) I86-I89
43. Kobelt G., Eberhardt K., Jonsson L., and Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis and Rheumatism 42 (1999) 347-356
44. Kobelt G., Jonsson L., Lindgren P., et al. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis and Rheumatism 46 (2002) 2310-2319
45. Michaud K., Messer J., Choi H., and Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis and Rheumatism 48 (2003) 2750-2762
46. Guillemin F. The value of utility: assumptions underlying preferences and quality adjusted life years. The Journal of Rheumatology 26 (1999) 1861-1863
47. Wong J.B., Singh G., and Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. The American Journal of Medicine 113 (2002) 400-408
48. Kobelt G., Jonsson L., Young A., and Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42 (2003) 326-335
49. Kobelt G., Eberhardt K., and Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Annals of the Rheumatic Diseases 63 (2004) 4-10
50. Brennan A., Bansback N., Reynolds A., and Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43 (2004) 62-72
51. Kavanaugh A., Han C., and Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. The Journal of Rheumatology 31 (2004) 849-855
52. Yelin E., Trupin L., Katz P., et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis and Rheumatism 48 (2003) 3046-3054
53. Bansback N.J., Brennan A., Sengupta N., and Pang F. The cost effectiveness of adalimumab (HUMIRA) in UK patients with moderate to severe RA [Abstract]. Annals of the Rheumatic Diseases 63 supplement 1 (2004) 512-513
54. Bansback N.J., Brennan A., and Sengupta N. The cost effectiveness of adalimumab (HUMIRA) in patients with RA: a Finnish analysis [Abstract]. Annals of the Rheumatic Diseases 63 supplement 1 (2004) 513-514
55. Choi H.K., Seeger J.D., and Kuntz K.M. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis and Rheumatism 43 (2000) 2316-2327
56. Kavanaugh A., Heudebert G., Cush J., and Jain R. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Seminars in Arthritis and Rheumatism 25 (1996) 297-307
57. Hallert E., Husberg M., Jonsson D., and Skogh T. Rheumatoid arthritis is already expensive during the first year of disease. Rheumatology 43 (2004) 1374-1382
58. Quinn M., Conaghan P., O'Connor P., et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthritis and Rheumatism 52 (2005) 27-35
59. Kavanaugh A., Krueger G., Yan S., et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. Arthritis and Rheumatism 50 supplement (2004) S318
60. Kobelt G., Sandlin-Sobocki P., Brophy S., et al. The burden of ankylosing spondylitis and the cost-effectiveness of treament with infliximab. Rheumatology 43 (2004) 1158-1166
61. Jonietz E. Generic biotech. Technology Review 107 (2004) 54-58
62. Bozzette S. Routine screening for HIV infection - timely and cost effective. The New England Journal of Medicine 352 (2005) 620-621
63. Rothberg M., and Rose D. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. The American Journal of Medicine 118 (2002) 68-77
64. Solomon D., and Kuntz K. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroids treatment be screened for osteoporosis?. Arthritis and Rheumatism 43 (2000) 1967-1975